PPARγ enhances IFNγ-mediated transcription and rescues the TGFβ antagonism by stimulating CIITA in vascular smooth muscle cells

Journal of Molecular and Cellular Cardiology

Volumn 46, Issue 5, 2009, Pages 748-757

  Kong, Xiaocen ^a   Fang, Mingming ^a,b   Fang, Fei ^a   Li, Ping ^a   Xu, Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Atherogenesis; CIITA; Collagen type I; IFN ; MHC II; PPAR ; Protein degradation; TGF ; Transcriptional regulation

Indexed keywords

COLLAGEN TYPE 1; GAMMA INTERFERON; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

AORTA MEDIA; ARTICLE; ATHEROGENESIS; BLOOD VESSEL WALL; CHROMATIN IMMUNOPRECIPITATION; CYTOKINE PRODUCTION; ENZYME ASSAY; HUMAN; HUMAN CELL; INFLAMMATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; SMOOTH MUSCLE FIBER; TRANSCRIPTION INITIATION; UPREGULATION; VASCULAR SMOOTH MUSCLE; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PROTEIN BINDING;

CELL LINE; HUMANS; INTERFERON-GAMMA; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NUCLEAR PROTEINS; PPAR GAMMA; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN STABILITY; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 63349106348     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.01.011     Document Type: Article

References (39)

1. Libby P. Inflammation in atherosclerosis. Nature 420 6917 (2002 Dec 19-26) 868-874
2. Jonasson L., Holm J., Skalli O., Gabbiani G., and Hansson G.K. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest. 76 1 (1985 Jul) 125-131
3. Rekhter M.D., Zhang K., Narayanan A.S., Phan S., Schork M.A., and Gordon D. Type I collagen gene expression in human atherosclerosis. Localization to specific plaque regions. Am. J. Pathol. 143 6 (1993 Dec) 1634-1648
4. Buttice G., Miller J., Wang L., and Smith B.D. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ. Res. 98 4 (2006 Mar 3) 472-479
5. Strutz F., and Neilson E.G. The role of lymphocytes in the progression of interstitial disease. Kidney Inter., Suppl. 45 (1994 Feb) S106-S110
6. Xu Y., Wang L., Buttice G., Sengupta P.K., and Smith B.D. Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon gamma (IFN-gamma). J. Biol. Chem. 279 40 (2004 Oct 1) 41319-41332
7. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 1 (2001 Jan) 48-52
8. Yavrom S., Chen L., Xiong S., Wang J., Rippe R.A., and Tsukamoto H. Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells. J. Biol. Chem. 280 49 (2005 Dec 9) 40650-40659
9. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., and Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106 4 (2000 Aug) 523-531
10. Moore K.J., Rosen E.D., Fitzgerald M.L., Randow F., Andersson L.P., Altshuler D., et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 7 1 (2001 Jan) 41-47
11. Xu Y., Farmer S.R., and Smith B.D. Peroxisome proliferator-activated receptor gamma interacts with CIITA x RFX5 complex to repress type I collagen gene expression. J. Biol. Chem. 282 36 (2007 Sep 7) 26046-26056
12. Piskurich J.F., Linhoff M.W., Wang Y., and Ting J.P. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol. Cell. Biol. 19 1 (1999 Jan) 431-440
13. Green M.R., Yoon H., and Boss J.M. Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility. J. Immunol. 177 6 (2006 Sep 15) 3865-3873
14. Grainger D.J. TGF-beta and atherosclerosis in man. Cardiovasc. Res. 74 2 (2007 May 1) 213-222
15. Hansson G.K., and Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev., Immunol. 6 7 (2006 Jul) 508-519
16. Katsuda S., and Kaji T. Atherosclerosis and extracellular matrix. J. Atheroscler. Thromb. 10 5 (2003) 267-274
17. Harvey E.J., and Ramji D.P. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?. Cardiovasc. Res. 67 1 (2005 Jul 1) 11-20
18. Higashi K., Inagaki Y., Fujimori K., Nakao A., Kaneko H., and Nakatsuka I. Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3. J. Biol. Chem. 278 44 (2003 Oct 31) 43470-43479
19. Dooley S., Said H.M., Gressner A.M., Floege J., En-Nia A., and Mertens P.R. Y-box protein-1 is the crucial mediator of antifibrotic interferon-gamma effects. J. Biol. Chem. 281 3 (2006 Jan 20) 1784-1795
20. Eickelberg O., Pansky A., Koehler E., Bihl M., Tamm M., Hildebrand P., et al. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J. 15 3 (2001 Mar) 797-806
21. Ghosh A.K., Yuan W., Mori Y., Chen S., and Varga J. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J. Biol. Chem. 276 14 (2001 Apr 6) 11041-11048
22. Tredget E.E., Wang R., Shen Q., Scott P.G., and Ghahary A. Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. J. Interferon Cytokine Res. 20 2 (2000 Feb) 143-151
23. Ricote M., Valledor A.F., and Glass C.K. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24 2 (2004 Feb) 230-239
24. Vega R.B., Huss J.M., and Kelly D.P. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20 5 (2000 Mar) 1868-1876
25. Hondares E., Pineda-Torra I., Iglesias R., Staels B., Villarroya F., and Giralt M. PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle. Biochem. Biophys. Res. Commun. 354 4 (2007 Mar 23) 1021-1027
26. Wu Z., Bucher N.L., and Farmer S.R. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol. Cell. Biol. 16 8 (1996 Aug) 4128-4136
27. Wu Z., Xie Y., Bucher N.L., and Farmer S.R. Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev. 9 19 (1995 Oct 1) 2350-2363
28. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 6993 (2004 Jun 17) 771-776
29. Fajas L., Egler V., Reiter R., Hansen J., Kristiansen K., Debril M.B., et al. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev. Cell 3 6 (2002 Dec) 903-910
30. Puigserver P., Adelmant G., Wu Z., Fan M., Xu J., O'Malley B., et al. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 286 5443 (1999 Nov 12) 1368-1371
31. Kwak B.R., Myit S., Mulhaupt F., Veillard N., Rufer N., Roosnek E., et al. PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells. Circ. Res. 90 3 (2002 Feb 22) 356-362
32. Willermain F., Dulku S., Gonzalez N.S., Blero D., Driessens G., De Graef C., et al. 15-Deoxy-12,14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanism. Prostaglandins Other Lipid Mediat. 80 3-4 (2006 Sep) 136-143
33. Fyfe A.I., Qiao J.H., and Lusis A.J. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J. Clin. Invest. 94 6 (1994 Dec) 2516-2520
34. Palinski W., Miller E., and Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 92 3 (1995 Jan 31) 821-825
35. Zhou X., Robertson A.K., Rudling M., Parini P., and Hansson G.K. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ. Res. 96 4 (2005 Mar 4) 427-434
36. Chyu K.Y., Reyes O.S., Zhao X., Yano J., Dimayuga P., Nilsson J., et al. Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (-/-) mice. Atherosclerosis 176 1 (2004 Sep) 27-35
37. Gonzalez-Santiago L., Lopez-Ongil S., Rodriguez-Puyol M., and Rodriguez-Puyol D. Decreased nitric oxide synthesis in human endothelial cells cultured on type I collagen. Circ. Res. 90 5 (2002 Mar 22) 539-545
38. Nagler A., Miao H.Q., Aingorn H., Pines M., Genina O., and Vlodavsky I. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler. Thromb. Vasc. Biol. 17 1 (1997 Jan) 194-202
39. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 24 (2007 Jun 14) 2457-2471